NKGEN BIOTECH INC (NKGN) Stock Price, Quote, News and Overview
NASDAQ:NKGN - Nasdaq - US65488A1016 - Common Stock - Currency: USD
NKGN Quote, Performance and Key Statistics
0.1913
-0.32 (-62.91%)
The current stock price of NKGN is 0.1913 USD. In the past month the price decreased by -59.77%. In the past year, price decreased by -91.22%.
NKGN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 324.18B | ||
| AMGN | AMGEN INC | 13.09 | 146.06B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 112.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.72B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6 | 26.02B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.84B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About NKGN
Company Profile
NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. The company is headquartered in Santa Ana, California and currently employs 63 full-time employees. The company went IPO on 2021-05-21. The firm is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. The company is developing SNK01, an autologous natural killer (NK) cell therapy, for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its autologous NK cell therapy candidate has clinical trials in several therapeutic areas, including oncology and neurodegeneration. SNK02 is its allogeneic NK cell product candidate. The company is conducting clinical trials with its SNK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).
Company Info
NKGEN BIOTECH INC
3001 Daimler St,
Santa Ana CALIFORNIA US
Employees: 63
Phone: 19493966830
NKGEN BIOTECH INC / NKGN FAQ
What is the stock price of NKGEN BIOTECH INC today?
The current stock price of NKGN is 0.1913 USD. The price decreased by -62.91% in the last trading session.
What is the ticker symbol for NKGEN BIOTECH INC stock?
The exchange symbol of NKGEN BIOTECH INC is NKGN and it is listed on the Nasdaq exchange.
On which exchange is NKGN stock listed?
NKGN stock is listed on the Nasdaq exchange.
What is NKGEN BIOTECH INC worth?
NKGEN BIOTECH INC (NKGN) has a market capitalization of 8.60M USD. This makes NKGN a Nano Cap stock.
How many employees does NKGEN BIOTECH INC have?
NKGEN BIOTECH INC (NKGN) currently has 63 employees.
Should I buy NKGEN BIOTECH INC (NKGN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NKGN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NKGN, evaluating the profitability, health, valuation and growth aspects
- NKGEN BIOTECH INC (NKGN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NKGEN BIOTECH INC (NKGN) Sales and EPS estimates to see what analysts future expectations are.
- NKGEN BIOTECH INC (NKGN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NKGEN BIOTECH INC (NKGN) Insider and Institutional Ownership to learn about the owners and their transactions.
- NKGEN BIOTECH INC (NKGN) Stock Chart to make your own analysis
- NKGEN BIOTECH INC (NKGN) Latest news and press-releases to stay up to date.
Does NKGEN BIOTECH INC (NKGN) stock pay dividends?
NKGN does not pay a dividend.
When does NKGEN BIOTECH INC (NKGN) report earnings?
NKGEN BIOTECH INC (NKGN) will report earnings on 2025-04-14.
What is the Price/Earnings (PE) ratio of NKGEN BIOTECH INC (NKGN)?
NKGEN BIOTECH INC (NKGN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.71).
What is the Short Interest ratio of NKGEN BIOTECH INC (NKGN) stock?
The outstanding short interest for NKGEN BIOTECH INC (NKGN) is 0.11% of its float. Check the ownership tab for more information on the NKGN short interest.
NKGN Technical Analysis
NKGN Financial Highlights
Over the last trailing twelve months NKGN reported a non-GAAP Earnings per Share(EPS) of -4.71. The EPS decreased by -50.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -564.01% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |